Abstract
Objective: The early differential diagnosis of Alzheimer's disease (AD) remains still problematic. We developed a laboratory test enabling us to distinguish patients with AD from those with vascular dementia (VD) and healthy subjects.
Methods: The AD group consisted of 22 women and 18 men. The VD group consisted of 16 women and 8 men. Age-matched controls consisted of 12 women and 9 men. Plasma pregnenolone sulfate (PregS), dehydroepiandrosterone (DHEA) and its sulfate (DHEAS) were determined by radioimmunoassay. 17-Hydroxypregnenolone (17 Preg) and 7-hydroxylated metabolites of DHEA (7αDHEA, 7βDHEA) were determined by radioimmunoassay after separation by high performance liquid chromatography (HPLC). Homocysteine (Hcy), cysteine (Cys), cysteinylglycine (Cysgly) and glutathione (GSH) were measured by HPLC.
Results: The ANOVA results of significant between-group differences were as follows: The PregS and the 17-Preg and DHEAS levels were independent from the diagnosis. The 7αDHEA levels significantly depended on the sex (p<0.05) and diagnosis (p<0.01). Aminothiols were influenced by the diagnosis (p<0.01, p=0.0541, p<0.01 and p=0.0536 for Cys, Hcy, Cysgly and GSH, respectively). Using a stepwise backward regression analysis, the following parameters were obtained: X=11.5+4.03×sex+1.09× Hcy+0.190 × PregS−4.76×DHEAS+3.00×DHEA− 34.3×7αDHEA−0.885× Cysgly from which P-value as a discriminator was calculated according to the formula: P=1/(1+e−x). Then, for P>0.5, a subject was considered as AD-positive (with 89% correct prediction).
Discussion: The opportunity of early differential diagnosis of AD should help physicians to use suitable treatment for retardation of pathological processes.
Copyright (c) 2004 by Walter de Gruyter GmbH & Co. KG
